Percorrer por autor "Nunes, Hugo"
A mostrar 1 - 3 de 3
Resultados por página
Opções de ordenação
- The effects of the leg position on the Nordic hamstring exercise eccentric force : a randomized cross-over studyPublication . Ferreira, Ricardo Maia; Martins, Pedro Nunes; Nunes, Hugo; Fernandes, Luís Gonçalves; Amorim, César Ferreira; Ferreira, Luciana Maia AlvesGiven the posterior chain configuration, it is anticipated that tibial positioning influences hamstring recruitment; medial hamstrings should be more activated during medial rotation, while lateral hamstrings should be more activated during lateral rotation. However, most studies showing this pattern have focused on concentric or isometric strength, leaving the influence on eccentric strength fairly unknown. Therefore, the aim of this study was to investigate the electromyographic response of the hamstring muscles during Nordic hamstring exercises in three leg positions: internal rotation, external rotation, and neutral. This study encompassed a randomized crossover study and used surface electromyography to analyze the activity of the biceps femoris and semitendinosus muscles during the Nordic hamstring exercise, in the three positions. Results indicated no statistically significant differences in muscle activation between positions or sides (p > 0.05), though small effect sizes were observed for the biceps femoris in different positions (η2 = 0.01–0.03). Furthermore, the internal rotation position generally elicited the highest muscle activations. Notably, biceps femoris muscles exhibited higher activations compared to semitendinosus muscles, with the greatest differences seen in the internal rotation position. This suggests that tibial rotation influences hamstring recruitment patterns; however, it was lower than expected.
- Modular buck-boost transformerless grid-tied inverter for low voltage solar panelsPublication . Nunes, Hugo; Pimenta, Nelson; Fernandes, Luís; Chaves, Paulo; Costa, J. M. DoresThis paper deals with a transformerless AC module for low DC voltage output photovoltaic solar panels. The DC to AC converter was designed to be a single-phase grid-tied inverter, and is based on a buck-boost topology with current mode control to shape the current and to adjust delivered power. The common ground node prevents voltage fluctuations and increases people´s safety. Low power inverters tend to be less efficient than larger ones and are prone to higher harmonic distortion. To overcome these drawbacks, special care was taken in designing the power stage, and harmonic compensation was included in the control stage. The inverter has MPPT capability and operates with unity power factor. Inverter´s operation is analysed, and some simulation results are presented. A 220Wp two-stage single-phase AC module prototype, with 240V and 50Hz sine-wave output, was build and connected to a low voltage photovoltaic solar panel. Experimental results for this plug-and-play converter are here presented.
- Real-world effectiveness of aromatase inhibitors and fulvestrant in HR+/HER2- advanced breast cancer : a snapshot of the last two years before conventional use of CDK 4/6 inhibitors in a Portuguese institutionPublication . Teodoro, Maria Inês; Mayer, Alexandra; Miranda, Ana da Costa; Nunes, Hugo; Costa, Filipa Alves da; Lourenço, AntónioBackground: Monotherapy with aromatase inhibitors and fulvestrant were the standard-of-care for hormone receptor-positive (HR+)/human epidermal growth factor receptor-type2 negative (HER2-) advanced breast cancer, before integration of cyclin-dependent kinase 4/6 inhibitors. Effectiveness data is essential for regulatory action, but little is known about real-world use of aromatase inhibitors and fulvestrant. Methods: A retrospective cohort study was conducted resorting to data from a cancer registry to identify adult women with HR+/HER2- advanced breast cancer exposed to aromatase inhibitors or fulvestrant (31 May 2017–31 March 2019) at the main oncology hospital in Portugal. Cases were updated with follow-up until death or cut-off (31 March 2021) and pseudoanonymized data extracted. Primary outcome was overall survival (OS) and secondary time to treatment failure (TTF), estimated using survival analysis and compared with published trials. Results: 192 patients were distributed by subgroups according to the medicine. Letrozole: OS 30.8 (95% confidence interval (CI) 20.6–41.4); TTF 11.2 (95%CI 8.7–13.7). Exemestane: OS 22.1 (95%CI 9.7–34.6); TTF 6.0 (95%CI 4.1–7.8). Fulvestrant: OS 21.6 (95%CI 16.5–26.7); TTF 5.6 (95%CI 4.5–6.6). Conclusions: Estimated effectiveness (OS) of letrozole and fulvestrant was, respectively, 3.2–3.5 months lower than reported. The clinical meaning seems uncertain and may be explained by a higher proportion of worse prognostic characteristics in patients treated in the real-world.